3.2 Adverse Event Classification and Reporting

Understanding and Classifying Adverse Events

Patient safety is the paramount concern in any clinical trial. A central component of ensuring safety is the systematic identification, classification, and reporting of adverse events. Clinical Research Coordinators (CRCs) must master the terminology and regulatory requirements surrounding safety reporting to ensure compliance and protect trial participants.

Defining Adverse Events (AEs) and Adverse Drug Reactions (ADRs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

An Adverse Drug Reaction (ADR), on the other hand, implies causality. In the pre-approval clinical experience with a new medicinal product, all noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions. The phrase "responses to a medicinal product" means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility.

Severity versus Seriousness: A Critical Distinction

One of the most common errors in clinical research is confusing the severity of an adverse event with its seriousness. These terms are not synonymous in regulatory language.

Severity refers to the clinical intensity of the event. It is a clinical grade. Common grading scales include the Common Terminology Criteria for Adverse Events (CTCAE), which categorizes severity as:

• Mild (Grade 1): Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
• Moderate (Grade 2): Minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living.
• Severe (Grade 3): Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling.
• Life-threatening (Grade 4): Life-threatening consequences; urgent intervention indicated.
• Death (Grade 5): Death related to AE.

Seriousness, conversely, is a regulatory definition based on patient/event outcome or action criteria. It serves as a guide for defining regulatory reporting obligations. An adverse event is considered a Serious Adverse Event (SAE) if it results in any of the following outcomes:

1. Results in death.
2. Is life-threatening: The patient was at immediate risk of death from the event as it occurred (it does not include an event that, had it occurred in a more severe form, might have caused death).
3. Requires inpatient hospitalization or prolongation of existing hospitalization.
4. Results in persistent or significant disability/incapacity.
5. Is a congenital anomaly/birth defect.
6. Is an important medical event: Events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed above (e.g., allergic bronchospasm requiring intensive treatment in an emergency room or at home).

Example: A subject experiences a severe headache that lasts for three hours but resolves with over-the-counter medication at home. The event is severe in intensity but is not serious because it did not result in death, hospitalization, or disability.

Causality Assessment and Expectedness

When an AE occurs, the Principal Investigator (PI) must assess two crucial factors: causality and expectedness.

Causality answers the question: Is there a reasonable possibility that the investigational product caused the adverse event? Investigators typically classify causality as:

• Not Related / Unlikely: The event is clearly due to extraneous causes (e.g., underlying disease, environment).
• Possible: The event follows a reasonable temporal sequence from administration, but could also be reasonably explained by the subject's clinical state or other therapies.
• Probable / Definite: The event follows a reasonable temporal sequence, abates upon withdrawal of the drug (dechallenge), and cannot be reasonably explained by the known characteristics of the subject's clinical state.

Expectedness asks: Is the nature or severity of the event consistent with the applicable product information? For an unapproved investigational drug, the reference document is the Investigator's Brochure (IB). If the event is not listed in the IB, or occurs with greater severity or specificity than described, it is considered unexpected.

Expedited Reporting: The SUSAR

When an event is Serious, Unexpected, and Suspected to be related to the investigational product, it is classified as a Suspected Unexpected Serious Adverse Reaction (SUSAR). SUSARs represent significant, unforeseen safety signals and trigger expedited reporting requirements to regulatory authorities (like the FDA or EMA) and all participating investigators.

CRCs are typically responsible for ensuring that the site's Principal Investigator completes the SAE report form immediately—usually within 24 hours of the site becoming aware of the event—so the sponsor can meet these tight regulatory deadlines. The sponsor then evaluates the SAE, determines if it is a SUSAR, and files the expedited IND safety report with the FDA.